- Home
- VTYX vs MSD Comparison
VTYX vs MSD Comparison
Compare VTYX & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- MSD
- Stock Information
- Founded
- VTYX 2018
- MSD 1993
- Country
- VTYX United States
- MSD United States
- Employees
- VTYX N/A
- MSD N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- MSD Trusts Except Educational Religious and Charitable
- Sector
- VTYX Health Care
- MSD Finance
- Exchange
- VTYX Nasdaq
- MSD Nasdaq
- Market Cap
- VTYX 154.9M
- MSD 159.9M
- IPO Year
- VTYX 2021
- MSD N/A
- Fundamental
- Price
- VTYX $2.08
- MSD $8.02
- Analyst Decision
- VTYX Buy
- MSD
- Analyst Count
- VTYX 4
- MSD 0
- Target Price
- VTYX $11.33
- MSD N/A
- AVG Volume (30 Days)
- VTYX 1.9M
- MSD 70.2K
- Earning Date
- VTYX 02-25-2025
- MSD 01-01-0001
- Dividend Yield
- VTYX N/A
- MSD 11.26%
- EPS Growth
- VTYX N/A
- MSD N/A
- EPS
- VTYX N/A
- MSD N/A
- Revenue
- VTYX N/A
- MSD N/A
- Revenue This Year
- VTYX N/A
- MSD N/A
- Revenue Next Year
- VTYX N/A
- MSD N/A
- P/E Ratio
- VTYX N/A
- MSD N/A
- Revenue Growth
- VTYX N/A
- MSD N/A
- 52 Week Low
- VTYX $1.67
- MSD $6.11
- 52 Week High
- VTYX $11.48
- MSD $7.46
- Technical
- Relative Strength Index (RSI)
- VTYX 45.64
- MSD 64.83
- Support Level
- VTYX $1.83
- MSD $7.56
- Resistance Level
- VTYX $2.61
- MSD $7.97
- Average True Range (ATR)
- VTYX 0.18
- MSD 0.14
- MACD
- VTYX -0.03
- MSD 0.05
- Stochastic Oscillator
- VTYX 32.26
- MSD 98.53
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.